



SYNTHESES AND ANTICANCER ACTIVITY OF RIBONUCLEOSIDE ANALOGUES CONTAINING THIO-SUBSTITUTED FIVE-MEMBERED HETEROCYCLIC BASE†

Yun Ding, Yun-Yan Zhang, Jiong Zhang^a, Yao-Quan Chen^{*}

*Laboratory of Bio-organic & Natural Products Chemistry
Shanghai Institute of Organic Chemistry, The Chinese Academy of Sciences
354 Fenglin Road, Shanghai 200032, China*

Abstract: Syntheses of two types of ribonucleoside analogues with thio-substituted five-membered heterocyclic base have been carried out. The one contains thio-substituted 1,3,4-triazole as its base (**2** to **7**) and the other consists of amino-thio-thiadiazoline β -D-ribofuranosides (**8** and **9**). Biological evaluation showed that one (**8**) among them exhibited IC_{50} of 3.94×10^{-8} mol/L against NCI CNS cancer cell line SNB19.

© 1997 Elsevier Science Ltd.

Nucleoside analogues are one important kind of antimetabolite agents which exhibit anticancer and antiviral activities. Their structural design and chemical synthesis have been extensively studied. Nucleoside analogues having five-membered heterocyclic base also cause wide attention. Among them, ribavirin, which contains a substituted triazole ring as its heterocyclic base, represents the most successful one.¹

Due to its soft nucleophilicity and reversible redox properties, sulfur atom plays an important role in the life processes. Nucleoside analogues containing sulfur atom in the sugar moiety or in the heterocyclic moiety have been synthesized and some of them have been found to be active against cancer cells or viruses.² It is therefore of interest to synthesize nucleoside analogues with thio-substituted five-membered ring as a heterocyclic base and examine their biological activities. Here we wish to report our results.


Chemical Synthesis

Syntheses of two types of the title compounds have been carried out. The first one includes ribonucleoside analogues containing thio-substituted 1,3,4-triazole as a heterocyclic base. The synthesis is shown in Scheme 1. Compound **1**, the central intermediate in this synthesis, was obtained by N-substitution of silver thiocyanate on 1-bromo-2,3,5-tri-O-benzoyl- β -D-ribofuranose followed by hydrazinolysis.³ Condensation of **1** with various acids, esters, amides, or anhydrides in anhydrous solvent gave products **2a-7a**, which were debenzoylated by sodium methoxide to give the final products **2b-7b**.⁴⁻⁹

†This paper is dedicated to the memory of Professor Yu Wang.

^aPresent address: Department of Chemistry, University of Iowa, Iowa City, IA 52242, USA.


Scheme 1



i. $\text{HCOOH}/(\text{CH}_3\text{CO})_2\text{O}/\text{DMAP}$, 50°C , 0.5h, 65%; ii. $\text{CH}_3\text{C}(\text{OCH}_3)_2/\text{CH}_2\text{Cl}_2$, refluxed, 10h, 65%;
 iii. $(\text{CF}_3\text{CO})_2\text{O}/\text{CH}_2\text{Cl}_2$, r.t., 1h, 55%; iv. $\text{Im}_2\text{CO}/\text{THF}$, r.t., 4h, 75%; v. CS_2 , refluxed, 4h, 64%;
 vi. $\text{NaNO}_2/\text{CH}_3\text{CO}_2\text{H}/\text{CH}_2\text{Cl}_2$, r.t., 10min, 83%; vii. $\text{CH}_3\text{ONa}/\text{CH}_3\text{OH}$, r.t., 4h.

The second type of the title compounds consists of amino-thio-thiadiazoline β -D-ribofuranosides, which were synthesized via both condensation and fusion procedures¹⁰ as shown in Scheme 2. Both of the procedures

Scheme 2



i. p-toluenesulfonic acid, $120-130^\circ\text{C}$, 20mmHg, 30min, 38% for **8a**, 15% for **9a**;
 ii. $\text{SnCl}_4/\text{CH}(\text{CH}_3)_2\text{Cl}$, r.t., 8h, 52% for **8a**, 29% for **9a**; iii. $\text{NaOCH}_3/\text{CH}_3\text{OH}$, r.t., 4h.

produced two positional isomers as proved by ^1H , ^{13}C NMR, mass spectra and elemental analysis data.^{11,12} The one with higher R_f value was assigned to be 4-(β -D-ribofuranosyl)-2-amino-5-thio-1,3,4-thiadiazoline (**8b**) by X-ray crystallographic analysis,¹³ therefore the other with lower R_f value was tentatively proposed to have the structure of 3-(β -D-ribofuranosyl)-2-imino-5-thio-1,2,4-thiadiazoline (**9b**). Further support came from the ^1H NMR signals of the amino and imino groups of the two compounds. Compound **8b** showed a symmetrical singlet (integrated 2H), which was due to two identical N-H protons; whereas **9b** gave a shouldered singlet (poorly resolved two singlet peaks, in total also integrated 2H), which was consistent with a ring NH and an imino NH.

Biological evaluation The *in vitro* biological evaluation performed by NCI NIH on NCI cancer cell lines showed that only **8b** exhibited IC_{50} of 3.94×10^{-8} mol/L against CNS cancer cell line SNB19. The other compounds did not display significant activities at the concentrations up to 10^{-4} mol/L.

Acknowledgements: The authors are grateful to The NCI NIH for the biological evaluation. We thank Professor C.K. Chu of College of Pharmacy, University of Georgia for his help in arrangement for the bio-assays.

References and notes

- Witkowski, J.T.; Robins, R.K.; Sidwell, R.W.; Simon, L.N. *J. Med. Chem.*, **1972**, *15*, 1150; *Ribavirin: A broad spectrum antiviral agent*, Smith, R.A. and Kirkpatrick, W., Ed.; Academic Press: New York, 1980.
- For examples, see Hirota, K.; Tomishi, T.; Maki, Y. *Heterocycles* **1987**, *26*, 3089; Belleau, B.; Dixit, D.; Nguyen-Ga, N.; Kraus, J.L. *At 5th International Conference on AIDS*, Montreal, Canada, June 4-9, 1989; Palomino, E.; Meltsner, B.R.; Kessel, D.; Horwitz, J.P. *J. Med. Chem.* **1990**, *33*, 258; Kung, P.P.; Jones, R.A. *Tetrahedron Lett.* **1991**, *32*, 3919; Secrist III, J.A.; Tiwari, K.N.; Riordan, J.M.; Montgomery, J.A. *J. Med. Chem.* **1991**, *33*, 2361; Wigerinck, P.; Snoeck R.; Claes, P.; De Clercq, E.; Herdewijn, P. *ibid.* **1991**, *34*, 1767; Dyson, M.R.; Coe, P.L.; Walker, R.T. *J. C. S. Chem. Commun.* **1991**, 741; Goodwin, J.T.; Glick, G.O. *Tetrahedron Lett.* **1993**, *34*, 5549; Jeong, L.S.; Nicklaus, M.C.; George, C.; Marquez, V.E. *ibid.* **1994**, *35*, 7569; 7573; Xiang, Y.; Teng, Q.; Chu, C.K. *ibid.* **1995**, *36*, 3781; Van Praanen, N.A.; Freeman, G.A.; Short, S.A.; Harvey, R.; Jansen, R.; Szczech, G.; Koszalka, G.W. *J. Med. Chem.* **1996**, *39*, 538; Rahim, S.G.; Trivedi, N.; Bogunovic-Batchelor, M.V.; Hardy, G.W.; Mills, G.; Selway, J.W.T.; Snowden, W.; Littler, E.; Coe, P.L.; Basnak, I.; Walker, R.T. *ibid.* **1996**, *39*, 789; Saluja, S.; Zou, R.; Drach, J.C.; Townsend, L.B. *ibid.* **1996**, *39*, 881; Nishizono, N.; Koike, N.; Yamagata, Y.; Fujii, S.; Matsuda, A. *Tetrahedron Lett.* **1996**, *37*, 925.
- Hohnjec, M.; Kobe, J.; Valcavi, U.; Japelj, M. *J. Heterocycl. Chem.*, **1975**, *12*, 909.
- 2a**, colorless needles from ethyl acetate, yield 65%. mp 180-182.5°C (lit.² 179-180°C). ¹H NMR (CDCl₃), 8.12-7.37 (m, 16H, PhH, 5H), 6.85 (d, 1H, 1'H), 5.91 (m, 2H, 2',3'H), 4.78 (m, 3H, 4',5'H). MS (m/z), 546 (MH⁺), 445 (M⁺ - base), 105 (Bz). **2b**, yield 84%. mp 135-135.5°C (lit.² 135-137°C). $[\alpha]_D^{20} = -12.1^\circ$ (c 1.0, CH₃OH). $\lambda_{max} = 256\text{nm}$ (ϵ 3.5×10^4). ¹H NMR (DMSO-d₆), 8.70 (s, 1H, 2H), 5.81 (d, 1H, 1'H, $J=4.47\text{Hz}$), 5.52 (d, 1H, OH, $J=5.63\text{Hz}$), 5.17 (m, 2H, OH), 4.19, 4.10, 3.90 (m, 3H, 2',3',4'H), 3.65-3.55 (m, 2H, 5'H). MS(m/z), 234 (MH⁺), 133 (M⁺ - base), 102 (base).
- 3a**: white powder, yield 65%. mp 217-218°C. ¹H NMR (CDCl₃), 8.10-7.34 (m, 15H, PhH), 5.92-5.76 (m, 3H, 1',2',3'H), 4.73-4.61 (m, 3H, 4',5'H), 2.56 (s, 3H, CH₃). ¹³C NMR (CDCl₃), 166.154-164.924 (PhCO, CS), 133.892-128.235 (C-Ph), 88.312 (1'C), 86.180, 79.729, 74.232 (2',3',4'C), 70.759 (5'C), 15.75 (CH₃). Elemental anal. calcd. for C₂₀H₂₃N₃O₄S: C, 62.25; H, 4.50; N, 7.51. Found: C, 62.21; H, 4.40; N, 7.39. **3b**, yield 41%. mp. 153.5-155 °C. $[\alpha]_D^{20} = -12.1^\circ$ (c 0.7, CH₃OH). ¹H NMR (CD₃OD), 5.13 (d, 1H, 1'H), 4.24 (m, 1H, 2'H), 3.92-3.63 (m, 4H, 3',4',5'H), 2.75 (s, 3H, CH₃). MS (m/z), 248 (MH⁺), 133 (M⁺ -base), 116 (base). HRFABMS, calcd. for C₈H₁₁N₃O₄S: 247.0627. Found: 247.0586.
- 4a**, white powder, yield 55%. mp 164-165°C. ¹H NMR (CDCl₃), 8.04-7.37 (m, 15H, PhH), 6.48 (br, NH), 6.16 (d, 1H, 1'H), 5.85 (m, 2H, 2',3'H), 4.68 (m, 3H, 4',5'H). ¹³C NMR (CDCl₃), 166.405-165.641 (PhCO), 163.053 (CS), 149.0 (CF₃), 134.115-128.640 (CPh), 86.510 (1'C), 79.965, 74.160, 71.731, (2',3',4'C), 64.085 (5'C). ¹⁹F NMR (CDCl₃), 12.30. MS, m/z, 445 (M⁺ - base), 105 (Bz), 69 (CF₃). Elemental anal. calcd. for C₂₀H₂₇F₃N₃O₄S: C, 56.77; H, 3.61; N, 6.85. Found: C, 56.67; H, 3.44; N, 6.87. **4b**, yield 62%. mp 230°C (dec.). $[\alpha]_D^{20} = -16.6^\circ$ (c 0.18, CH₃OH). UV (CH₃OH), $\lambda_{max} = 270\text{nm}$ (ϵ 1.6×10^5), $\lambda_{min} = 233$. ¹H NMR (CD₃OD), 5.21(d, 1H, 1'H, $J = 8.29\text{Hz}$), 4.90 (m, 2H, 2',3'H), 4.29 (m, 1H, 4'H), 3.89 (m, 2H, 5'H). ¹³C NMR (CD₃OD), 173.791 (CS), 126.700, 123.100, 119.514, 115.900 (q, CF₃, $J = 3.59\text{Hz}$), 84.750 (1'C), 72.229, 71.817, 66.892 (2',3',4'C), 65.797 (5'C). ¹⁹F NMR (CD₃OD), 10.50. MS (m/z), 302 (MH⁺), 170 (base + 2H), 133 (M⁺ - base). HRFABMS, calcd. for C₈H₁₀F₃N₃O₄S: 301.0344. Found: 301.0355.
- 5a**, white powder, yield 75%. mp 90.5-93°C. ¹H NMR (CDCl₃), 8.08-7.27 (m, 15H, PhH), 5.98-5.69 (m, 3H, 1',2',3'H), 4.73-4.57(m, 3H, 4',5'H). ¹³C NMR (CDCl₃), 169.550, 152.237 (CS, CO), 166.312-164.945

- (PhCO), 133.955-128.610 (CPh), 86.832 (1'C), 83.656, 74.223, 70.892 (2',3',4'C), 64.186 (5'C). MS (m/z), 561 (M⁺), 445 (M⁺ - base), 117 (base), 105 (Bz). HREIMS, calcd. for C₂₈H₂₃N₃O₈S: 561.1206. Found: 561.1200. **5b**, yield 60%. mp 220 (dec.). [α]_D²⁰ = -2.6 (c 1.0, H₂O). UV (H₂O), λ_{max} = 256nm (ϵ 4.8 × 10⁵), λ_{min} = 204nm. ¹H NMR (D₂O), 4.95 (s, 1H, 1'H), 4.16 (m, 1H, 2'H), 3.91-3.81 (m, 2H, 3',4'H), 3.57 (m, 2H, 5'H). MS(m/z), 272 (M + Na⁺), 250 (MH⁺), 115 (base). HRFABMS, calcd. for C₇H₁₂N₃O₅S: 250.0498. Found: 250.0502.
8. **6a**, white powder, yield 64%. mp 89-90°C. ¹H NMR (CDCl₃), 8.08-7.26 (m, 15H, PhH), 5.90-5.52 (m, 3H, 1',2',3'H), 4.73-4.58 (m, 3H, 4',5'H). ¹³C NMR (CDCl₃), 183.82 (CS), 166.207-164.850 (PhCO), 160.14 (CSH), 133.974-128.207 (CPh), 87.522 (1'C), 84.338, 74.089, 70.749 (2',3',4'C), 63.81 (5'C). MS(m/z), 579 (MH⁺), 445 (M-base), 134 (base), 105 (Bz). Elemental anal. calcd. for C₂₈H₂₃N₃O₈S₂: C, 58.22; H, 4.01; N, 7.27. Found: C, 58.60; H, 4.18; N, 6.91. **6b**, yield 71%. mp 202-204°C. [α]_D²⁰ = 18.3° (c 0.6, CH₃OH). UV(CH₃OH), λ_{max} = 300nm (ϵ 0.6 × 10⁴), λ_{min} = 252nm. ¹H NMR (CD₃OD), 4.83 (s, 1H, 1'H), 4.69 (m, 1H, 2'H), 3.89 (m, 1H, 3'H), 3.64 (m, 1H, 4'H), 3.49 (m, 2H, 5'H). MS(m/z), 265 (M⁺), 133 (base + H⁺ or ribosyl). HRFABMS, calcd. for C₇H₁₁N₃O₅S₂: 265.0191. Found: 265.0185.
9. **7a**, colorless needles from ethyl acetate, yield 83%. mp 112-114°C. ¹H NMR (CDCl₃), 8.10-7.33 (m, 15H, PhH), 5.93-5.75 (m, 3H, 1',2',3'H), 4.81-4.57 (m, 3H, 4',5'H). MS(m/z), 547 (M⁺ + 1), 445 (M⁺ - base), 105 (Bz). Elemental anal. calcd. for C₂₇H₂₃N₄O₈S: C, 59.33; H, 4.06; N, 10.25. Found: C, 59.01; H, 3.89; N, 9.97. **7b**, yield 45%. mp 220-221°C. [α]_D²⁰ = -47.6° (c 0.82, CH₃OH). UV(CH₃OH), λ_{max} = 220nm (ϵ 3.4 × 10⁵), λ_{min} = 250nm. ¹H NMR (CD₃OD), 6.39 (d, 1H, 1'H, *J* = 3.05Hz), 4.76 (m, 1H, 2'H), 4.60 (m, 1H, 3'H), 4.29 (m, 1H, 4'H), 3.98-3.79 (m, 2H, 5'H). MS(m/z), 133 (M⁺ - base), 102 (base). HRMS calcd. for CH₂N₄S (base), 102.0000. Found, 102.0000.
10. Ueda, T. In *Chemistry of Nucleosides and Nucleotides*, Townsend, L.B. Ed.; Plenum Press: New York and London, 1988. Vol. 1. pp. 2-5; Srivastava, P.C.; Robins, R.K.; Meyer, Jr., R.B. *ibid.*, pp. 130-136.
11. **8a**, ¹H NMR (DMSO-d₆), 7.40-7.99 (m, 17H, PhH, NH), 6.73 (d, 1H, 1'H, *J* = 1.2Hz), 5.99 (m, 2H, 2',3'H), 4.84 (m, 1H, 4'H), 4.55, 4.66 (m, 2H, 5'H). ¹³C NMR (DMSO-d₆), 182.410, 158.260 (heterocyclic C), 166.230, 165.380, 164.470 (PhCO), 134.000-128.310 (PhC), 87.260, 79.100, 78.590, 74.390, 70.750 (sugar C). MS (m/z), 577 (M⁺), 445 (M⁺ - base). Elemental anal. calcd. for C₂₈H₂₃N₃O₇S₂: C, 58.23; H, 4.01; N, 7.28. Found: C, 58.10; H, 3.55; N, 6.84. **8b**, prismatic crystals from methanol, mp 195-196°C. ¹H NMR (DMSO-d₆), 7.30 (s, 2H, NH, D₂O exchangeable), 6.24 (d, 1H, 1'H, *J* = 3.7Hz), 5.38, 5.06 (d, 2H, 2',3'-OH, *J* = 5.9, 5.6Hz), 4.71 (t, 1H, 5'-OH, *J* = 5.8Hz), 4.21 (m, 1H, 2'H), 4.05 (m, 1H, 3'H), 3.83 (m, 1H, 4'H), 3.43-3.53 (m, 2H, 5'H). ¹³C NMR (DMSO-d₆), 181.740, 157.630 (heterocyclic C), 89.150, 84.910, 73.500, 70.560, 62.310 (sugar C). MS (m/z), 265 (M⁺), 133 (base). Elemental anal. calcd. for C₇H₁₁N₃O₄S₂: C, 31.70; H, 4.18; N, 15.85. Found: C, 31.57; H, 4.03; N, 15.75.
12. **9a**, ¹H NMR (DMSO-d₆), 7.42-8.03 (17H, PhH, NH), 5.91 (d, 1H, 1'H, *J* = 3.6Hz), 5.79 (m, 2H, 2',3'H), 4.80 (m, 1H, 4'H), 4.63-4.53 (m, 2H, 5'H). ¹³C NMR (DMSO-d₆), 171.67, 144.23 (heterocyclic C), 166.370, 164.620, 164.380 (PhCO), 133.800-128.750 (PhC), 87.220, 80.080, 74.640, 71.350, 63.630 (sugar C). MS (m/z), 600 (M + Na⁺), 445 (M-base). Elemental anal. calcd. for C₂₈H₂₃N₃O₇S₂: C, 58.23; H, 4.01; N, 7.28. Found: C, 57.98; H, 3.84; N, 6.74. **9b**, foam-like solid, ¹H NMR (DMSO-d₆), 7.37 (s with shoulder, 2H, NH, D₂O exchangeable), 5.19 (d, 1H, 1'H, *J* = 4Hz), 5.45, 5.04 (d, 2H, 2',3'-OH, *J* = 4, 5.5Hz), 4.76 (t, 1H, 5'H, *J* = 3.7Hz), 3.97 (m, 1H, 2'H), 3.90 (m, 1H, 3'H), 3.81 (m, 1H, 4'H), 3.40-3.45 (m, 2H, 5'H). ¹³C NMR (DMSO-d₆), 170.960, 147.190 (heterocyclic C), 90.380, 85.790, 75.050, 70.630, 61.790 (sugar C). MS(m/z), 288 (M + Na⁺), 266 (MH⁺).
13. Measured on Rigaku AFC7R diffractometer with graphite monochromated Mo-K α radiation and a 12kW rotating anode generator. Monoclinic crystal system with space group of P2₁ (#4), *a* = 6.809(2), *b* = 8.985(2), *c* = 9.130(1), β = 103.93(1)°. *Z* = 2. *V* = 542.2(2) Å³, *D_c* = 1.600g/cm³.

(Received in Japan 7 April 1997; accepted 19 May 1997)